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Canine gastric dilatation–volvulus (GDV) is a life-threatening disease characterized by exten-
sive tissue ischemia, tissue hypoperfusion, and systemic inflammation. Biomarkers that 
better reflect the severity of gastric necrosis and systemic inflammation would aid clinicians 
in the management of these patients. This study aimed to investigate the prognostic sig-
nificance of cell-free DNA (cfDNA), high-mobility group box-1 (HMGB1), and procalcitonin 
(PCT) in dogs with GDV. Concentrations of cfDNA, HMGB1, and PCT were measured in 
citrated plasma samples collected from 29 dogs with GDV at hospital admission. Additional 
data collected included baseline lactate concentrations, APPLEfast score, evidence of gastric 
necrosis, occurrence of postoperative complications, and outcome. Twenty-four healthy 
dogs were sampled as controls. Continuous variables between groups were compared 
with the Mann–Whitney U and correlations between continuous variables were assessed 
by calculation of Spearman’s correlation coefficient. Alpha was set at 0.05. Dogs with GDV 
had significantly greater concentrations of cfDNA, HMGB1, and PCT compared to controls 
(P = 0.0009, P = 0.004, and P = 0.009, respectively). PCT concentrations were significantly 
higher in non-survivors compared to survivors (P = 0.008). Dogs with gastric necrosis had 
significantly greater lactate concentrations compared to dogs without gastric necrosis 
(P = 0.0005). The APPLEfast score was not prognostic. Lactate and PCT concentrations 
were moderately, positively correlated (rs 0.51, P = 0.0005). Concentrations of the inflam-
matory biomarkers cfDNA, HMGB1, and PCT are increased in canine GDV. Only lactate and 
PCT concentrations were prognostic in this population of GDV dogs and were predictive 
of the presence of gastric necrosis and of non-survival to hospital discharge, respectively.
Keywords: cell-free Dna, procalcitonin, high-mobility group box-1, biomarker, gastric necrosis, ischemia–reperfusion 
injury, prognosis
inTrODUcTiOn
Canine gastric dilatation–volvulus (GDV) syndrome is a life-threatening emergency, characterized by 
pain, abdominal distension, systemic inflammation, and severe tissue hypoperfusion. The pathophysi-
ology of the disease involves rapid intragastric gas accumulation, volvulus, and progressive increases 
in intragastric pressure. Increased tissue pressure causes ischemia with local cell injury and death that 
Abbreviations: APP, acute phase protein; APPLE, acute patient physiologic and laboratory evaluation; cfDNA, cell-free DNA; 
GDV, gastric dilatation–volvulus; HMGB1, high-mobility group box-1; PCT, procalcitonin; SIRS, systemic inflammatory 
response syndrome.
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can progress to tissue necrosis. Hypovolemia from third-space 
fluid loss, coupled with obstructive shock due to decreased venous 
return rapidly follow, leading to secondary organ dysfunction (1). 
The prognosis for GDV is favorable with early diagnosis, timely 
medical stabilization, and prompt surgical correction (2). Systemic 
complications can develop during the course of the syndrome or 
in the early postoperative period, however, including sepsis and 
reperfusion injury that can lead to multiple organ dysfunction and 
death (1, 2). The presence and the extent of gastric necrosis are 
reported as a strong predictor of mortality in GDV dogs (1).
Dogs with GDV frequently fulfill the criteria for the presence 
of systemic inflammatory response syndrome (SIRS) (3). Tissue 
hypoperfusion, cellular necrosis, and ischemia-reperfusion 
injury are the main triggers of SIRS in the perioperative period 
(3, 4), and increased plasma concentrations of SIRS-associated 
biomarkers, such as C-reactive protein and high-mobility group 
box-1 (HMGB1) have been reported in GDV dogs (4, 5). Blood 
lactate concentrations have been demonstrated to be prognostic in 
GDV syndrome (1). Serial lactate monitoring has been advocated 
in the postoperative period to identify surgical dehiscence (1) 
and decreased lactate clearance has been associated with gastric 
necrosis and mortality (6, 7). The prevalence of hyperlactatemia 
at presentation is variable in dogs with GDV, however, and base-
line lactate concentrations are not consistently prognostic (5–7). 
Hence, there is a need for novel biomarkers that are prognostic 
early in the course of GDV syndrome, and that parallel the extent 
of tissue ischemia and systemic inflammation.
Plasma cell-free DNA (cfDNA) has been receiving growing 
attention as a biomarker in critically ill humans. The precise origin 
of this circulating cfDNA remains unclear, but cells undergoing 
necrosis or apoptosis in addition to leukocytes forming extracel-
lular traps are the most likely sources (8, 9). In healthy people 
and in healthy dogs, plasma cfDNA concentrations are low, while 
increased concentrations have been detected in many conditions 
characterized by systemic inflammation and extensive tissue 
injury (10). Independent of the underlying disease, cfDNA con-
centrations reflect the severity of cell damage and are prognostic 
in cardiac arrest, ischemia/reperfusion injury, shock, trauma, and 
sepsis (9–12). The veterinary literature in this area is limited, but 
increased blood cfDNA concentrations have been documented 
in dogs with immune-mediated hemolytic anemia, cancer, sep-
sis, and trauma (13–15). A positive correlation between cfDNA 
concentration and disease severity has also been documented in 
a heterogeneous group of clinically ill dogs (16).
High-mobility group box-1 is a non-histone chromosomal 
protein that is highly conserved among species. In humans, 
HMGB1 is released passively after cellular necrosis (but not 
apoptosis), and is actively released from inflammatory cells as a 
late-phase cytokine (17). In the intravascular space, HMGB1 acts 
as an alarmin—a damage-associated molecular pattern that serves 
to enhance inflammation. HMGB1 plays a significant role in the 
course of ischemia–reperfusion injury and vasculitis (17, 18), and 
increased concentrations of HMGB1 have been documented in 
sick dogs (19–22). Concentrations of HMGB1 are of prognostic 
value in dogs with lymphoma, SIRS, and GDV (4, 19, 23).
Procalcitonin (PCT), the prohormone of calcitonin, has 
emerged as a diagnostic and prognostic biomarker in human 
sepsis. Concentrations of PCT can differentiate sepsis from non-
infectious SIRS, be used to monitor response to therapy and to 
predict sepsis-related complications and prognosis (24, 25). The 
utility of circulating plasma PCT in dogs has been investigated in 
several studies. Baseline PCT concentration predicted organ dys-
function and serial PCT concentrations were related to outcome 
in canine sepsis (26). However, PCT was not able to differentiate 
dogs with sepsis from dogs with non-septic SIRS or non-septic 
SIRS from healthy control dogs (27). Although previous studies 
proposed PCT as a novel acute phase protein (APP) (28), its clini-
cal value has not been extensively evaluated in dogs with systemic 
inflammation.
Thus, the aim of the current study is to assess the prognos-
tic value of cfDNA, HMGB1, and PCT in dogs with GDV. We 
hypothesized that (1) concentrations of cfDNA, HMGB1, and 
PCT are increased at the time of presentation in dogs with GDV 
compared to healthy controls; (2) these biomarkers predict 
occurrence of gastric necrosis, postoperative complications, and 
survival to discharge; (3) concentrations of these biomarkers are 
positively correlated with each other, with lactate concentration 
and with an established illness severity score.
MaTerials anD MeThODs
animals
Canine plasma samples were collected from dogs managed at 
the two participating veterinary teaching hospitals (Cornell 
University, Ithaca, NY, USA and University of Bologna, Italy). 
Specifically, stored citrated plasma samples collected from dogs 
with GDV (Cornell n = 21, Bologna n = 8) enrolled as part of 
other studies were analyzed. Those studies were approved by the 
local Institutional Animal Care and Use Committees (IACUC), 
and undertaken under written informed client consent (Cornell 
IACUC 2014-0053; Bologna DL 26/2014, Project 581).
Inclusion criteria for this study included a diagnosis of GDV, 
and availability of an aliquot of citrated plasma collected at the 
time of admission and stored frozen at −80°C. The diagnosis 
of GDV syndrome was based on compatible clinical signs and 
the presence of characteristic gas distension and displacement 
of the stomach on right lateral abdominal radiographs (29). 
Respective primary clinicians determined all aspects of case 
management. Dogs euthanized at the time of presentation were 
excluded.
Twenty-four healthy privately owned dogs were enrolled as 
controls (Cornell IACUC 2014-0052; Bologna project ID 581). 
These dogs were eligible for inclusion if they had no history or 
evidence of recent or chronic medical conditions and had not 
received any medication, except for routine preventative health 
care, within the preceding 3 months. Dogs were classified healthy 
on the basis of history, physical examinations, and complete 
blood count and serum chemistry results.
clinical and clinicopathologic Data 
collection
From the dogs with GDV, the following data were recorded: 
physical examination findings at presentation, the presence 
TaBle 1 | Concentrations of measured inflammatory biomarkers in dogs with 
GDV compared to healthy controls.
Biomarker control dogs 
(n = 24)
gDV dogs  
(n = 29)
P
Cell-free DNA (ng/mL) 471 (334–640) 530 (418–3,070) 0.0009
HMGB1 (ng/mL)a 1.6 (0.3–10.9) 4.5 (1.5–62.8) 0.004
Procalcitonin (ng/mL)a 39.8 (9.7–92.3) 65.5 (14.2–480.6) 0.009
Data are presented as median (min–max). P-values in bold type were significant at 
P < 0.05.
aGDV dogs n = 28.
GDV, gastric dilatation–volvulus; HMGB1, high-mobility group box-1.
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or absence of gastric necrosis intraoperatively, the occurrence 
and nature of postoperative complications. Outcome was 
defined as survival to hospital discharge, death, or euthanasia. 
In presence of operable gastric necrosis, a partial gastrectomy 
was performed. If gastric necrosis was deemed inoperable 
according to the attending surgeon, dogs underwent intraop-
erative euthanasia. Blood was collected at the time of presenta-
tion and prior to patient stabilization for baseline laboratory 
analyses, including measurement of lactate concentrations 
(Lactate Pro 2, Arkray, Minneapolis, MN, USA; Lactate Scout 
Analyzer, Senslab, Leipzig, Germany). Blood collected into 
citrated plasma tubes containing 3.2% sodium citrate (1:9 
ratio) were centrifuged (3,000  g for 10  min) immediately 
after collection, the supernatant decanted, and stored frozen 
at −80°C until analysis. Citrated plasma samples used in this 
study were collected between July 2015 and March 2017, 
with analyses performed in June 2017. Patient clinical and 
clinicopathologic data were used to evaluate the Acute Patient 
Physiologic and Laboratory Evaluation (APPLEfast) score as 
previously reported (30).
cfDna, hMgB-1, and PcT evaluation
All biomarkers were measured as a batch at Cornell University. 
Samples from Bologna were transported to Cornell on dry ice 
by overnight courier. All samples were frozen on arrival and 
were stored at −80°C prior to analysis. All three analytes are 
reportedly stable for prolonged periods at −80°C (31–33). 
Citrated plasma samples were thawed at 37°C just prior 
to analysis. Measurement of cfDNA was performed with a 
fluorescence-based method using DNA-specific fluorophores 
(Quant-iT High Sensitivity DNA assay Kit, Life Technologies, 
Grand Island, NY, USA) as previously reported in dogs (14). 
Reagents were used per manufacturer’s instruction. Canine 
HMGB1 was quantified by means of a commercially available 
human sandwich ELISA kit (IBL-International, Hamburg, 
Germany) previously validated for use in dogs (20). PCT con-
centrations were measured using a commercial canine ELISA 
kit (Biovendor LLC, Asheville, NC, USA). Absorbance values 
for the ELISA assays were measured using a microplate reader 
(BioTek Instruments, Winooski, VT, USA). To improve within-
run precision, concentrations of cfDNA were measured in 
triplicate. Owing to cost constraints, concentrations of HMGB1 
and PCT were measured in duplicate only. All assays have coef-
ficients of variation ≤10%. The mean values of replicates were 
used for subsequent analyses.
statistical analysis
Prior to test selection, data were assessed for normality by assess-
ment of histograms, calculation of skewness and kurtosis and 
with the D’Agostino Pearson test. Descriptive statistics were cal-
culated as appropriate. Most data were nonparametric. Data are, 
therefore, presented as median (min–max). The Mann–Whitney 
U-test was used to compare continuous variables between groups. 
Spearman’s correlation coefficient was used to assess correla-
tions between variables. Alpha was set at 0.05. All analyses were 
performed using commercially available software (Prism 6.0, 
GraphPad Software, La Jolla, CA, USA).
resUlTs
Demographics
Twenty-nine dogs with GDV were enrolled. The study popu-
lation included 12 castrated male dogs, 8 intact male dogs, 
7 spayed female dogs, and 2 intact female dogs. The median 
age was 9  years (0.8–14). The median bodyweight was 37  kg 
(17.0–72.3). The median rectal temperature on presentation 
was 38.3°C (36.5–40.5), the median heart rate was 160  bpm 
(80–220), the median respiratory rate was 48  rpm (24–120). 
The median APPLEfast score was 23 (10–40) and the median 
duration of hospital stay was 2 days (0–5). Of the 29 dogs, 6 
were seen by a primary care veterinarian prior to assessment 
at the study institutions. All six were radiographed. Only three 
dogs received treatment prior to presentation at the study 
centers including fluid therapy (n =  2) and opioid analgesia 
(n  =  2). Twenty-two dogs (76%) were discharged from the 
hospital and were considered survivors, while seven dogs (24%) 
did not survive to hospital discharge. All non-survivors were 
humanely euthanized. No dog was euthanized due to financial 
constraints. Evidence of gastric necrosis was detected in seven 
dogs during surgery: four dogs were euthanized intraopera-
tively for inoperable necrosis; 1 underwent partial gastrectomy 
but was euthanized later in the course of hospital stay for severe 
complications; 2 underwent partial gastrectomy and survived 
to hospital discharge. Twenty-two dogs had no evidence of gas-
tric necrosis at the time of surgery. Of these, dogs 20 survived, 
while 2 were euthanized during the course of hospital stay for 
late complications. Systemic complications were reported in 
four dogs, and included pneumonia (n = 2), septic peritonitis 
(n =  1), and disseminated intravascular coagulation (n =  1). 
Twenty-four dogs were enrolled as controls. There were 13 
spayed female dogs, 6 castrated male dogs, 3 intact female 
dogs, and 2 intact male dogs. The median age of the controls 
was 4  years (1–13), and the median body weight was 26  kg 
(5–62). The median age and body weight of GDV dogs were 
significantly higher compared to control dogs (P = 0.0002 and 
P = 0.010, respectively).
cfDna, hMgB1, and PcT comparisons
The median concentrations of cfDNA (n  =  29), HMGB1 
(n = 28), and PCT (n = 28) were significantly greater in dogs 
with GDV compared to controls (P = 0.0009, P = 0.004, and 
P  =  0.009, respectively) (Table  1; Figure  1). There was no 
FigUre 2 | Box and whisker plot comparison of plasma procalcitonin (PCT) 
concentrations in 28 dogs with gastric dilatation–volvulus syndrome 
categorized as survivors (n = 21) and non-survivors (n = 7). The central line 
represents the median, the boxes represent the interquartile range, and the 
whiskers represent the minimum and maximum values. * indicates statistical 
significance at P < 0.05. Non-survivors had significantly greater plasma 
concentrations of PCT compared to survivors by Mann–Whitney U-test 
(P = 0.008).
TaBle 2 | Comparison of the variables under analysis in GDV dogs according to 
final outcome and presence of gastric necrosis.
Biomarker survivors  
(n = 22)
non-survivors  
(n = 7)
P
Cell-free DNA (cfDNA) (ng/mL) 523 (418–677) 534 (484–3,070) 0.35
HMGB1 (ng/mL)a 4.5 (1.5–13.7) 5.9 (1.5–62.8) 0.32
Procalcitonin (PCT) (ng/mL)a 53.7 (14.2–419.2) 186.4 (43.3–480.6) 0.008
Lactate (mmol/L) 2.8 (1.1–10.6) 5.2 (2.6–11.9) 0.05
APPLEfast score 23 (12–40) 22 (10–35) 0.76
Biomarker gastric necrosis 
absent (n = 22)
gastric necrosis 
present (n = 7)
P
cfDNA (ng/mL) 523 (418–677) 547 (446–3,070) 0.43
HMGB1 (ng/mL)b 4.5 (1.5–13.8) 5.9 (1.6–62.8) 0.60
PCT (ng/mL)b 61.5 (20.5–419.2) 82.5 (14.2–480.6) 0.57
Lactate (mmol/L) 2.5 (1.1–10.6) 9.7 (4.9–11.9) 0.0005
APPLEfast score 23 (12–40) 25 (19–35) 0.17
Data are presented as median (min–max). P-values in bold type were significant at 
P < 0.05.
an = 21 survivors.
bn = 21 gastric necrosis absent.
GDV, gastric dilatation–volvulus; HMGB1, high-mobility group box-1.
FigUre 1 | Box and whisker plot comparisons of plasma concentrations of cell-free DNA (cfDNA), high-mobility group box-1 (HMGB1), and procalcitonin (PCT) 
from 24 healthy control dogs and 29 dogs with gastric dilatation–volvulus (GDV) syndrome. The central line represents the median, the boxes represent the 
interquartile range and the whiskers represent the minimum and maximum values. * indicates statistical significance at P < 0.05. Dogs with GDV had significantly 
greater plasma concentrations of cfDNA, HMGB1 (n = 28) and PCT (n = 28) compared to healthy controls by Mann–Whitney U-test (P = 0.0009, P = 0.004, and 
P = 0.009, respectively).
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difference between the cfDNA or HMGB1 concentrations of 
survivors and non-survivors (P =  0.35 and P =  0.32, respec-
tively), but median PCT concentrations were significantly 
greater in non-survivors compared to survivors (P =  0.008) 
(Table  2; Figure  2). The difference in PCT concentrations 
between survivors and non-survivors remained significant 
even after the exclusion of the three dogs developing septic 
complications. There was no difference between the cfDNA, 
HMGB1, or PCT concentrations of dogs with or without gastric 
necrosis (P =  0.67, P =  0.26, and P =  0.66, respectively), or 
between dogs developing postsurgical complications compared 
to dogs that did not develop complications (P = 0.69, P = 0.59, 
and P = 0.06, respectively) (Table 2).
additional results
Mortality rate was significantly higher in dogs with gastric necro-
sis compared to dogs without gastric necrosis 5/7 (71.4%) vs. 2/22 
(9.1%) (P = 0.003). The median blood lactate concentration was 
significantly higher in dogs with gastric necrosis compared to 
dogs without gastric necrosis (P = 0.0007) (Table 2; Figure 3), 
but lactate concentration was not different between survivors and 
non-survivors (P = 0.053), or between dogs with versus without 
postsurgical complications (P = 0.30). The APPLEfast score was 
not different between survivors and non-survivors (P =  0.76), 
between dogs with versus without gastric necrosis (P =  0.17), 
FigUre 3 | Box and whisker plot comparison of blood lactate 
concentrations from 22 dogs with gastric dilatation–volvulus (GDV) without 
gastric necrosis, and 7 dogs with GDV and gastric necrosis. The central line 
represents the median, the boxes represent the interquartile range, and the 
whiskers represent the minimum and maximum values. * indicates statistical 
significance at P < 0.05. Dogs with gastric necrosis had significantly higher 
lactate concentrations compared to dogs without gastric necrosis by 
Mann–Whitney U-test (P = 0.0005).
FigUre 4 | Comparison of plasma procalcitonin and blood lactate 
concentrations in 28 dogs with gastric dilatation–volvulus (GDV) syndrome. 
Spearman’s rank correlation coefficient (rs) 0.51, P = 0.0005.
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or between dogs with or without postsurgical complications 
(P = 0.96). Blood lactate and plasma PCT concentrations were 
moderately and significantly positively correlated (rs 0.51, 
P = 0.0005) (Figure 4), but no other significant correlations were 
identified between any of the biomarkers themselves or between 
blood lactate concentrations and APPLEfast score.
DiscUssiOn
The present study investigated the prognostic ability of novel 
biomarkers of cellular damage and inflammation in dogs with 
GDV. Consistent with our hypothesis and in agreement with the 
existing literature, dogs with GDV syndrome had significantly 
greater median plasma cfDNA, HMGB1, and PCT concentrations 
compared to healthy controls. Human and canine data suggests 
that cfDNA in the plasma derives from neutrophil extracellular 
trap formation and cell death (9, 10, 14). As such, the greater 
concentrations of cfDNA documented in GDV dogs could origi-
nate from gastric ischemia and necrosis, or from tissue damage 
resulting from global hypoperfusion and systemic inflammation. 
Similar mechanisms likely explain the increased HMGB1 con-
centrations documented in our GDV dogs compared to healthy 
dogs, as HMGB1 can be passively released by necrotic cells (17). 
Interestingly, however, concentrations of cfDNA and HMGB1 
were not significantly correlated, which points to different sources 
of these two biomarkers. Given that it is a late-phase cytokine, 
the increases in HMGB1 concentration noted may indicate SIRS 
rather than local gastric tissue injury (19).
Increased transcription of PCT mRNA has been reported 
in canine SIRS due to infectious and non-infectious causes 
(28, 34), and a resultant increase in circulating PCT protein 
has been documented in septic dogs (26, 27). The causes of the 
increased circulating PCT concentrations in dogs with GDV are, 
as yet, unknown. PCT may act as an APP, as previously suggested 
(28), or it may be associated with septic phenomena during GDV 
syndrome, since bacterial translocation has been reported in dogs 
with GDV (35), and septic complications (e.g., septic peritonitis) 
are commonly documented perioperatively (2, 3).
It was hypothesized that cfDNA and HMGB1 reflect the 
degree of cell damage and, therefore, would predict gastric necro-
sis and outcome in canine GDV. Data from the present study do 
not support this hypothesis, however, because neither of these 
biomarkers correlated with gastric necrosis or were prognostic 
in this population. It is possible that the cfDNA concentrations 
are not predictive because they represent a single snapshot of 
cell damage/necrosis at the time of presentation. The processes 
causing gastric necrosis continue until the point of surgical 
correction and hence cfDNA concentration might escalate from 
the time of presentation to the time of surgery. Obtaining these 
samples would be more logistically difficult, but might be more 
discriminant than observation at presentation. As a parallel, 
although cfDNA concentrations are prognostic in humans with 
bacteremia (36, 37), they are not prognostic in cardiac arrest, 
a syndrome characterized by ischemia and reperfusion injury 
(9). Additionally, mechanisms other than necrosis have been 
postulated to explain the increase in plasma concentrations of 
cfDNA in people, including neutrophil extracellular trap forma-
tion and the active release of cfDNA as a method of intercellular 
communication (8, 10).
Uhrikova et  al. reported HMGB1 to be prognostic in dogs 
with GDV, wherein higher baseline and postsurgery concentra-
tions were documented in non-survivors (4). Those authors 
hypothesized that given the peracute nature of GDV syndrome 
and the kinetics of HMGB1 release, the increase in HMGB1 
reflected gastric necrosis rather than systemic hypoperfusion and 
inflammation (4). The median HMGB1 concentrations measured 
in GDV dogs in the present study (in both survivors and non-
survivors) are comparable with the values reported for survivors 
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only in the study by Uhrikova et al. This suggests that the dogs in 
the present study may have been less affected overall than those 
previously reported. Additional dissimilarities between the two 
study populations, such as time from onset of clinical signs to pres-
entation, and potential variations in assay conduct may account 
for the divergent results. Three dogs in the present study received 
treatment prior to study enrollment. Given the small number of 
dogs that received therapy prior to blood sampling, it is unlikely 
that this impacted our findings; however, we cannot completely 
exclude an effect on biomarker concentrations. None of the dogs 
that received prior treatment died or had gastric necrosis.
Surprisingly, no correlation was documented between cfDNA 
and HMGB1. Although plasma concentrations of both these 
biomarkers indicate the release of cellular nucleic acids into cir-
culation, their increase might be regulated by different pathways 
with distinct kinetics. To date, only weak correlations have been 
reported between cfDNA and DNA-histone-complexes in people 
after cardiac arrest (9), and between cfDNA and HMGB1 in dogs 
with sepsis (38). The lack of correlation between the two biomark-
ers and lactate concentrations might also reflect different stimuli 
for the release of these markers.
Procalcitonin measured in samples collected at the time of 
presentation was the only variable able to predict outcome in this 
population of GDV dogs, although it should be noted that there 
was considerable overlap in the PCT concentrations between 
these two groups. PCT is a promising biomarker to aid in sepsis 
diagnosis and prognostication in people (39–41), and there is 
limited but growing evidence that PCT might also be a useful bio-
marker in dogs (28, 34). An earlier effort to measure PCT in dogs 
was unsuccessful, owing to problems with the ELISA (42), but the 
present study used a different assay from the Floras et al. study. 
PCT clearance is prognostic in dogs with sepsis, and baseline 
PCT was associated with the occurrence of organ dysfunction 
and septic shock (26). Although the prognostic value of baseline 
PCT remains unclear in people and dogs with sepsis (27, 43), its 
usefulness in the course of canine GDV syndrome may result from 
the typically short duration of this disease. The difference in PCT 
concentrations between survivors and non-survivors remained 
significant even after the exclusion of the three dogs developing 
septic complications, suggesting a utility of PCT in GDV dogs 
beyond an association with the development of sepsis. Previous 
studies have not documented a relationship between C-reactive 
protein and outcome in dogs with GDV (4, 5). A comparison 
between PCT and other more well-established canine APPs was 
beyond the scope of the present study, but would be of interest. 
Further investigation will be necessary to determine whether 
PCT behaves as an APP during GDV, if it mirrors SIRS severity, 
or if it relates to the development of late organ dysfunction.
The moderate positive correlation identified between plasma 
PCT and blood lactate concentrations in the present study is 
consistent with the relationships between these biomarkers and 
the development of complications in these patients. The present 
study again serves to confirm the clinical value of lactate measure-
ments in dogs with GDV, since this was the only biomarker that 
was related to the presence of gastric necrosis. It should be noted, 
however, that no cut-off value that was 100% sensitive and specific 
for gastric necrosis, owing to the degree of overlap between the 
two groups. Lactate measurement is inexpensive and easy to per-
form at the point of care. Although PCT measurement appeared 
to offer useful information in these dogs, there is currently no 
commercial point-of-care test for canine PCT, limiting the ease of 
measurement. Development of such an assay might enhance the 
ability of clinicians to manage dogs with GDV, however.
The present study has some limitations. A convenience sam-
pling method was used, which limited the number of samples 
available for analysis. This may have reduced the power of some of 
our analyses. The identification and the assessment of the severity 
of gastric necrosis was subjective. Some dogs were euthanized 
based on these assessments and as such, it cannot be determined 
what the outcome would have been in those patients had surgery 
been completed and the dogs allowed to recover from anesthesia. 
Although blood sample collection was performed prospectively, 
medical records were retrospectively reviewed. In some cases, some 
data were missing. For example, time from onset of clinical signs 
to presentation, or time from presentation to the start of surgery 
were not universally determined. As such, the relationship between 
these factors could not be assessed and their potential impact on the 
biomarkers concentrations is unknown. Finally, minor differences 
in the management of the enrolled GDV dogs (stabilization meas-
ures, anesthetic protocols, surgical procedures, and postoperative 
care) between the two teaching hospitals involved in the study may 
have influenced the outcomes and introduced variability.
In conclusion, concentrations of cfDNA and HMGB1 are 
increased in dogs with GDV, potentially due to cellular dam-
age, systemic inflammation, and tissue hypoperfusion. Neither 
cfDNA or HMGB1 concentrations were prognostic in the 
present population of dogs with GDV. In contrast, plasma PCT 
concentrations were predictive of outcome and were moderately, 
positively correlated with lactate concentrations. Blood lactate 
concentrations were the only biomarker to correlate with the 
presence of gastric necrosis. The combination of lactate and PCT 
concentrations might provide valuable guidance for clinicians 
managing dogs with GDV.
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